Strategic partnerships MedComp Sciences has a track record of partnering with local institutions and events (City of Zachary, Lane Regional Medical Center, COVID-19 testing for championships). This suggests opportunities to offer extended clinical testing services, PCR testing campaigns, and pharmacogenetic-guided therapy programs to regional hospitals, clinics, and municipal health initiatives.

Expanding service lines The combination of urine drug testing and pharmacogenetics indicates a capability to support personalized medicine and medication management. Sales opportunities exist to position end-to-end pharmacogenomic testing for prescribers, pain management clinics, and addiction treatment centers seeking data-driven therapy optimization.

Regulatory health focus With involvement in COVID-19 testing for high-profile events and partnerships with medical centers, there is potential to scale for compliant, scalable clinical lab services to regional health systems, urgent-care networks, and public health programs seeking reliable diagnostic partners.

Mid-market fit Company size (11-50 employees) and revenue in the sub-10M range align with targeting small to mid-sized hospitals, clinics, and independent laboratories that need flexible, cost-effective toxicology and pharmacogenetics testing without enterprise-scale procurement.

Digital visibility Existing technology stack and online presence (SEO, analytics, forms) indicate readiness for lead generation and client onboarding enhancements. A sales play could include marketing automation, targeted content for clinicians about pharmacogenetics, and streamlined partner onboarding to accelerate new client acquisition.